Form 8.3 - Advanced Medical Solutions Group plc

Octopus Investments disclosed interests of 14,394,833 Advanced Medical Solutions Group ordinary shares, equal to 6.52% of the class, as of 8 October 2026. It reported selling 5,000 shares at 2.8225 per share and transferring 5,370 shares out in specie. The filing disclosed no related indemnity or dealing arrangements.

Analysis

The useful signal is the continuing 6.52% stake, not the 5,000-share sale: that sale is negligible relative to the disclosed holding and does not, on its own, indicate a change in Octopus Investments’ view. The in-specie transfers should not be read as open-market selling or a reduction in economic exposure without identifying the recipient vehicles and beneficial ownership. In a takeover context, a holder of this size may matter to voting arithmetic and perceived deal certainty, but the filing reports no commitment to support or oppose a transaction. It therefore provides ownership visibility, not evidence of offer terms, premium, or completion probability.

Near term, this is unlikely to justify a directional trade absent a separate offer announcement or price response. Over the next 1–3 months, monitor subsequent Rule 8 disclosures for meaningful stake changes and any disclosed voting commitment; those would be more informative about deal dynamics. The key reversal risk is that the small sale is followed by materially larger disposals, or that Octopus publicly signals opposition to an offer. Conversely, a support commitment could reduce perceived execution risk. No valuation, offer terms, trading liquidity, or recipient details are supplied, so do not infer a takeover-arbitrage spread or a free-float impact from this filing alone.

Key Decisions for Investors

• No trade on this disclosure alone; treat the reported sale as immaterial relative to the remaining position.
• For any existing event-driven position in Advanced Medical Solutions Group, track subsequent Rule 8 filings and formal statements for changes in Octopus’s ownership or voting stance.
• Do not classify the in-specie transfers as market selling until recipients and beneficial ownership are verified.
• Reassess only if a material stake reduction, explicit offer support/opposition, or formal offer terms change the probability or economics of a transaction.